The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: Relationships with abnormal E‐cadherin and catenin expression and microsatellite instability
Abstract
The causes and functional consequences of E‐cadherin (E‐CD) loss in breast cancer are poorly understood. E‐CD loss might act in concert with alterations in the APC/β‐catenin pathway to permit oncogenic β‐catenin signaling. To test this hypothesis, we have analyzed the presence of genetic and epigenetic alterations affecting E‐CD (CDH1), APC and β‐catenin (CTNNB1) genes and the immunohistochemical expression of E‐CD, β‐ and γ‐catenin in a series of 46 infiltrating lobular breast carcinomas (ILCs). Since 80% of ILCs featured complete loss of E‐CD expression, we analyzed the molecular alterations responsible for E‐CD inactivation in these tumors. We found that 10 of 46 (22%) cases harbored mutations in CDH1, including 1 case with 2 different mutations (1 of which was germline). CDH1 was also inactivated by loss of heterozygosity (LOH; 30/41, 73%) and promoter hypermethylation (19/46, 41%). Interestingly, LOH and mutations were also detected in the corresponding in situ lesions of the ILCs, implying that these alterations are early events in lobular cancer tumorogenesis. Additionally, the presence of a polymorphism in the CDH1 promoter was found to be inversely correlated with CDH1 mutations, but not with E‐CD levels. We next examined whether alterations in the APC/β‐catenin pathway also occurred in the same series of ILCs. Although no CTNNB1 or APC mutations were detected, promoter methylation (25/46, 52%) and LOH (7/30, 23%) of APC were found. Moreover, methylation of APC and CDH1 occurred concordantly. However, β‐ and γ‐catenin were severely reduced or absent in 90% of these tumors, implying that alterations in CDH1 and APC genes do not promote β‐catenin accumulation in ILC. These molecular alterations were not associated with microsatellite instability. In summary, several different mechanisms (mutations, LOH, methylation) are involved in the frequent CDH1 inactivation in invasive and in situ lobular breast cancer. The same tumors also show genetic and epigenetic alterations of APC gene. However, altered CDH1 and APC genes do not promote β‐catenin accumulation in this tumor type. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polakis, P. (2000) · Genes & Development · doi:10.1101/gad.14.15.1837 · Cited by 3,183
Cited by
Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
Ciriello, G., Gatza, M. L., Beck, A. H., Wilkerson, M. D., Rhie, S. K., Pastore, A., Zhang, H., McLellan, M., Yau, C., Kandoth, C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.033 · Cited by 1,858
Peinado, H., Ballestar, E., Esteller, M., & Cano, A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.1.306-319.2004 · Cited by 763
Self-citationHereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond
Hansford, S., Kaurah, P., Li-Chang, H., Woo, M., Senz, J., Pinheiro, H., Schrader, K. A., Schaeffer, D. F., Shumansky, K., Zogopoulos, G., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2014.168 · Cited by 694
Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities
Xu, X., Zhang, M., Xu, F., & Jiang, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01276-5 · Cited by 588
Metadata
- Authors
- Sarrió, D., Moreno‐Bueno, G., Hardisson, D., Sánchez‐Estévez, C., Guo, M., Herman, J. G., Gamallo, C., Esteller, M., & Palacios, J.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2003-05-08
- Volume
- 106
- Issue
- 2
- Pages
- 208-215
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2010231795
- Cited by
- 209
- References
- 1
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.